Kallyope
Deciphering the gut-brain axis through AI-driven drug discovery for transformative therapeutics.
AI-driven drug discovery via synergistic Pleotherapy for orphan diseases.
The Pharnext Pleo-Platform represents a specialized technical architecture in the biopharmaceutical space, focusing on the discovery and development of 'Pleo-treatments.' Unlike traditional drug discovery that seeks a single 'silver bullet' molecule, this AI platform utilizes advanced biological network modeling and big data analytics to identify synergistic combinations of existing, off-patent drugs. By 2026, the platform's positioning has shifted towards high-throughput genomic mapping and the licensing of its computational IP following the corporate restructuring of Pharnext SA. The technical core relies on network pharmacology, where the AI maps the interactome—the complex web of interactions between genes and proteins—to identify nodes where low-dose drug combinations can achieve high therapeutic efficacy with minimal toxicity. This approach significantly reduces the R&D timeline and clinical risk compared to de novo drug synthesis. The platform integrates transcriptomic data, clinical trial outcomes, and chemical libraries to predict how multi-target interventions will perform in specific patient subpopulations, particularly in neurodegenerative and rare conditions like Charcot-Marie-Tooth disease (CMT1A).
Maps the whole-genome interactome to identify multiple intervention points for a single disease.
Deciphering the gut-brain axis through AI-driven drug discovery for transformative therapeutics.
Accelerating drug discovery through an end-to-end generative AI pipeline for target identification, molecular design, and clinical trial prediction.
The industry-standard interactive visualization tool for integrated exploration of large-scale genomic datasets.
Unlocking the causal biology of disease through Gemini Digital Twins.
Verified feedback from the global deployment network.
Post queries, share implementation strategies, and help other users.
Proprietary algorithm that calculates the potentiation effect of drug A on drug B.
Correlates drug-induced gene expression changes with disease-associated gene signatures.
Predicts poly-pharmacy interactions and metabolic interference.
A curated library of over 2,000 off-patent drugs with detailed biological footprints.
Models how different biological signaling pathways influence each other under multi-drug pressure.
Uses AI to identify which genetic phenotypes will respond best to specific Pleo-treatments.
Lack of effective treatments for Charcot-Marie-Tooth disease type 1A.
Registry Updated:2/7/2026
High failure rate of de novo Alzheimer's drugs.
High-dose oncology treatments causing severe organ damage.